| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2000;69:732-738
© 2000 The Society of Thoracic Surgeons
a Second Department of Surgery, Nihon University School of Medicine, Tokyo, Japan
Address reprint requests to Dr Akira Sezai, Second Department of Surgery, Nihon University School of Medicine, 30-1 Oyaguchi-kamimachi, Itabashi-ku, Tokyo, 173-8610, Japan
Background. We evaluated the effects of human atrial natriuretic peptide (hANP) during cardiopulmonary bypass (CPB).
Methods. Forty patients undergoing coronary artery bypass grafting were investigated. A group of patients given hANP for 24 hours from the start of CPB (hANP group) was compared with a non-hANP group. Parameters examined were hemodynamics, urine volume, dosage of furosemide, respiratory index, pleural effusion, ANP, cyclic guanosine monophosphate, renin activity (renin), angiotensin-II, aldosterone, and glomerular filtration rate.
Results. Central venous pressure, systemic vascular resistance index, and pulmonary vascular resistance index were significantly lower in the hANP group than in the non-hANP group. The hANP group showed significantly higher levels of ANP, cyclic guanosine monophosphate, glomerular filtration rate, and respiratory index, and significantly lower levels of renin, angiotensin-II, aldosterone, and pleural effusion, as compared with the non-hANP group. The dosage of furosemide was significantly lower and the urine volume was significantly larger in the hANP group.
Conclusions. hANP can satisfactorily compensate for the shortcomings of CPB by decreasing the peripheral vascular resistance, suppressing the renin-angiotensin-aldosterone system, and exerting a strong diuretic effect.
This article has been cited by other articles:
|
|
 |
|
  H. H. Chen, T. M. Sundt, D. J. Cook, D. M. Heublein, and J. C Burnett Jr Low Dose Nesiritide and the Preservation of Renal Function in Patients With Renal Dysfunction Undergoing Cardiopulmonary-Bypass Surgery: A Double-Blind Placebo-Controlled Pilot Study Circulation, September 11, 2007; 116(11_suppl): I-134 - I-138. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Mentzer Jr, M. C. Oz, R. N. Sladen, A. H. Graeve, R. F. Hebeler Jr, J. M. Luber Jr, N. G. Smedira, and on behalf of the NAPA Investigators Effects of Perioperative Nesiritide in Patients With Left Ventricular Dysfunction Undergoing Cardiac Surgery: The NAPA Trial J. Am. Coll. Cardiol., February 13, 2007; 49(6): 716 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Kristeller, H. Papps, and R. F. Stahl Risk of worsening renal function with nesiritide following cardiac surgery Am. J. Health Syst. Pharm., December 1, 2006; 63(23): 2351 - 2353. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Brancaccio, G. Michielon, R. M Di Donato, D. Costa, F. Falzea, and F. Miraldi Atrial natriuretic factor in normothermic and hypothermic cardiopulmonary bypass Perfusion, May 1, 2004; 19(3): 157 - 162. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Hayashi, M. Ohtani, T. Hiraishi, and Y. Kobayashi Postoperative synthetic human atrial natriuretic peptide infusion and oral spironolactone administration for a patient with giant atria and low plasma level of atrial natriuretic peptide J. Thorac. Cardiovasc. Surg., July 1, 2002; 124(1): 206 - 209. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Peter Brunner-La Rocca, W. Kiowski, D. Ramsay, and G. Sutsch Therapeutic benefits of increasing natriuretic peptide levels Cardiovasc Res, August 15, 2001; 51(3): 510 - 520. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
